Transforming growth factor-β signaling and its role in cancer

Experimental Oncology

Volumn 24, Issue 1, 2002, Pages 3-12

  Souchelnytskyi, S ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

Smad; Transforming growth factor ; Tumorigenesis

Indexed keywords

APC PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; POLYPEPTIDE; SMAD PROTEIN; TRANSCRIPTION FACTOR SP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

APOPTOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; FRAMESHIFT MUTATION; GENE DELETION; GENE EXPRESSION; GENE INSERTION; HUMAN; HUMAN CELL; MISSENSE MUTATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0036225802     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. Growth factors from murine sarcoma virus-transformed cells
2. The sequence of the human genome
3. Initial sequencing and analysis of the human genome
4. Transforming growth factor βs: Biochemistry and biological activities in vitro and in vivo
5. Distortion of growth control in cancer cells
6. TGF-beta signaling by Smad proteins
7. Smads: Transcriptional activators of TGF-β responses
8. TGF-β signal transduction
9. Signaling of transforming growth factor-beta family members through Smad proteins
10. Specificity, diversity, and regulation in TGFβ superfamily signaling
11. Receptors for transforming growth factor-beta
12. Smad regulation in TGF-beta signal transduction
13. The role of TGF-β signaling in cancer
14. Role of Ras and Mapks in TGFbeta signaling
15. The transforming growth factor beta's
16. Transforming growth factor-beta 1 is a new form of tumor suppressor with true haploid insufficiency
17. Analysis of p53, p21WAF1, and TGF-beta 1 in human ductal adenocarcinoma of the pancreas: TGF-beta 1 protein expression predicts longer survival
18. Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis
19. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice
20. Targeted deletion of the TGF-beta 1 gene causes rapid progression to squamous cell carcinoma
21. TGF-β signaling blockade inhibits PHrP secretion by breast cancer cells and bone metastases development
22. Cyclosporin induces cancer progression by a cell-autonomous mechanism
23. The hallmarks of cancer
24. Growth factors in the extracellular matrix
25. Transforming growth factor-β1 increased survival of human melanoma through stroma remodeling
26. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance
27. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implication for a possible role of tumor cell/host TGF-b breast cancer progression
28. Regulation of proinflammatory effects of Fas ligand (CD95L)
29. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes
30. T cell suppressor factor from human glioblastoma cells is a 12.5-kD protein closely related to transforming growth factor-beta
31. Deactivation of macrophages by transforming growth factor-beta
32. Transforming growth factor β1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: Aberrant histocompatibility antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype
33. Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
34. Expression of growth factors, growthinhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis
35. Excessive production of transforming growth factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth
36. Positive correlation of plasma transforming growth factor-β1 levels with tumor vascularity in hepatocellular carcinoma
37. Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro
38. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells
39. TGF-beta receptors and DNA repair genes, coupled targets in a pathway of human colon carcinogenesis
40. TGF-beta signaling in tumor suppression and cancer progression
41. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer
42. Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic human gastrointestinal cancer
43. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer
44. Mutational analysis of transforming growth factor beta receptor type II and DNA mismatch repair genes in sporadic endometrial carcinomas with microsatellite instability
45. Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas
46. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma
47. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer
48. Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers
49. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers
50. A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma
51. Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer
52. Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma
53. Transforming growth factor beta type II receptor (TGF beta RII) mutation in gastric lymphoma without mutator phenotype
54. HNPCC associated with germline mutation in the TGF-beta type II receptor gene
55. Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis
56. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in situ and invasive carcinomas
57. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues
58. Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung
59. Down-regulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis
60. Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma
61. Transforming growth factor-beta type II receptors and Smad proteins in follicular thyroid tumors
62. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients
63. Resistance to TGF-beta 1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein - Barr virus-transformed B lymphoblastoid cell lines
64. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein
65. 5-azaC treatment enhances expression of transforming growth factor-beta receptors through down-regulation of Sp3
66. Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines
67. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis
68. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells
69. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene
70. Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis
71. Transforming growth factor-beta type II receptor confers tumor suppressor activity in murine renal carcinoma (Renca) cells
72. Overexpression of transforming growth factor beta-type II receptor reduces tumorigenicity and metastatic potential of K-ras-transformed thyroid cells
73. Increased TGF beta type II receptor expression suppresses the malignant phenotype and induces differentiation of human neuroblastoma cells
74. Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis
75. Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases
76. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer
77. Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers
78. TbetaR-I(6A) is a candidate tumor susceptibility allele
79. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas
80. Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency
81. Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer
82. Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas
83. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues
84. Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma
85. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line
86. Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas
87. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III
88. Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells
89. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells
90. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer
91. Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues
92. Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan - Riley - Ruvalcaba syndromes
93. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma
94. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
95. Homozygous deletion map at 18q21.1 in pancreatic cancer
96. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers
97. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma
98. Allelic imbalance in chromosome band 18q21 and SMAD4 mutations in ovarian cancers
99. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors
100. A novel SMAD4 gene mutation in seminoma germ cell tumors
101. Mutations in the SMAD4/DPC4 gene in juvenile polyposis
102. DPC4 splice variants in neuroblastoma
103. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease
104. Somatic alterations of the DPC4 and Madr2 genes in colorectal cancers and relationship to metastasis
105. Frequent loss of Smad4/DPC protein in colorectal cancers
106. Expression of Smad proteins in human colorectal cancer
107. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression
108. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes
109. Loss of heterozygosity in spontaneous and X-ray-induced intestinal tumors arising in F1 hybrid min mice: Evidence for sequential loss of APC(+) and Dpc4 in tumor development
110. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice
111. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4
112. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway
113. Dpc4 transcriptional activation and dysfunction in cancer cells
114. DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells
115. Transfer of chromosome 18 into human head and neck squamous carcinoma cells: Evidence for tumor suppression by Smad4/DPC4
116. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis
117. MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma
118. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma
119. Infrequent DPC4 gene mutation in esophageal cancer, gastric cancer and ulcerative colitis-associated neoplasms
120. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma
121. Inactivation of Smad4 in gastric carcinomas
122. DPC4 gene in various tumor types
123. DPC4 gene mutation in colitis associated neoplasia
124. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers
125. Transforming growth factor beta 1: Implications in adrenocortical tumorigenesis
126. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway
127. Somatic alterations of the SMAD-2 gene in human colorectal cancers
128. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma
129. MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma
130. Smad2 and Smad4 gene mutations in hepatocellular carcinoma
131. No mutations of the Smad2 gene in human sporadic gastric carcinomas
132. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers
133. Frequency of Smad gene mutations in human cancers
134. Genomic structure of the human Smad3 and its infrequent alterations in colorectal cancer
135. Mutational analysis of the tumor suppressor Smad2 in acute lymphoid and myeloid leukemia
136. Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4
137. Mechanism for mutational inactivation of the tumor suppressor Smad2
138. Smad2 role in mesoderm formation, left-right pattering and craniofacial development
139. Smad3 mutant mice develop metastatic colorectal cancer
140. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein
141. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: Functional implications for transforming growth factor beta signaling
142. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling
143. No SMAD4 hypermethylation in colorectal cancer
144. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras
145. Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells
146. Regulation of Smad signaling by protein kinase C
147. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer
148. Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer
149. High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells